A comparison of the platinum analogues in bladder cancer cell lines.
作者： Thomas Powles , Jacky Perry , Jonathan Shamash , Wai Liu , Tim Oliver
DOI: 10.1159/000102917
关键词: Platinum 、 Oncology 、 Oxaliplatin 、 Medicine 、 Broad spectrum 、 Bladder cancer 、 Internal medicine 、 Clinical trial 、 Drug 、 Bladder cancer cell
摘要: Background: Oxaliplatin is a 3rd generation platinum analogue, which active in broad spectrum of tumours. Clinical trials using this drug bladder cancer are underway, but no
karger.com
sci-hub.se 参考文章(17)
Pendyala L, Creaven Pj, In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Research. ,vol. 53, pp. 5970- 5976 ,(1993)
Jan M. Woynarowski, Sandrine Faivre, Maryanne C.S. Herzig, Brenda Arnett, William G. Chapman, Alex V. Trevino, Eric Raymond, Stephen G. Chaney, Alexandra Vaisman, Maria Varchenko, Paul E. Juniewicz, Oxaliplatin-induced damage of cellular DNA. Molecular Pharmacology. ,vol. 58, pp. 920- 927 ,(2000) , 10.1124/MOL.58.5.920
Eric D. Scheeff, James M. Briggs, Stephen B. Howell, Molecular Modeling of the Intrastrand Guanine-Guanine DNA Adducts Produced by Cisplatin and Oxaliplatin Molecular Pharmacology. ,vol. 56, pp. 633- 643 ,(1999) , 10.1124/MOL.56.3.633
P J Loehrer, L H Einhorn, P J Elson, E D Crawford, P Kuebler, I Tannock, D Raghavan, R Stuart-Harris, M F Sarosdy, B A Lowe, A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Journal of Clinical Oncology. ,vol. 10, pp. 1066- 1073 ,(1992) , 10.1200/JCO.1992.10.7.1066
Sibylle Nebel, Randolph D. Christen, Stefan Aebi, Stephen B. Howell, Hua Zheng, Bruno Cenni, Alissar Nehmé, Daniel Fink, The role of DNA mismatch repair in platinum drug resistance. Cancer Research. ,vol. 56, pp. 4881- 4886 ,(1996)
Christine Bonnal, Vincent Ravery, Mariane Toublanc, Guylène Bertrand, Laurent Boccon-Gibod, Dominique Hénin, Bernard Grandchamp, Absence of microsatellite instability in transitional cell carcinoma of the bladder Urology. ,vol. 55, pp. 287- 291 ,(2000) , 10.1016/S0090-4295(99)00399-4
W M Liu, L A Stimson, S P Joel, The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. British Journal of Cancer. ,vol. 86, pp. 1472- 1478 ,(2002) , 10.1038/SJ.BJC.6600288
Christine R. Culy, Delyth Clemett, Lynda R. Wiseman, Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. ,vol. 60, pp. 895- 924 ,(2000) , 10.2165/00003495-200060040-00005
A Nehmé, R Baskaran, S Nebel, D Fink, S B Howell, J Y J Wang, R D Christen, Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells British Journal of Cancer. ,vol. 79, pp. 1104- 1110 ,(1999) , 10.1038/SJ.BJC.6690176
Joan Carles, Miguel Nogué, Gemcitabine/carboplatin in advanced urothelial cancer. Seminars in Oncology. ,vol. 28, pp. 19- 24 ,(2001) , 10.1016/S0093-7754(01)80005-1